Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polaprezinc Combined Triple Therapy for Helicobacter pylori Associated Gastritis
ChiCTR-IIR-16009688Phase 4Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of polaprezinc in Helicobacter pylori infection and gastritis (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Helicobacter pylori eradication rate. Started Jan 2014; status: completed.
02
Drugs
polaprezinc
03
Conditions
Helicobacter pylori infectiongastritis
Beyond the preview
Go deeper on ChiCTR-IIR-16009688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16009688.